Abstract: Provided are methods and nucleic acids for detecting, differentiating or distinguishing between colon cell proliferative disorders by analysis of one or more of the genes Versican, TPEF, H-Cadherin, Calcitonin, and EYA4. Further provided are novel nucleic acid sequences useful for the cell proliferative disorder specific analysis of said genes as well as methods, assays and kits thereof.

Abstract: The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for ascertaining genetic and/or epigenetic parameters of genes for use in the differentiation, diagnosis, treatment and/or monitoring of colon cell proliferative disorders, or the predisposition to colon cell proliferative disorders.

Abstract: The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for predicting the disease free survival and/or response of a subject with a cell proliferative disorder of the breast tissues, to endocrine treatment.

Abstract: The invention provides methods and nucleic acids for detecting, differentiating or distinguishing between colon cell proliferative disorders as well as therapy thereof by analysis of the gene EYA4 and its promoter and regulatory sequences. The invention further provides novel nucleic acid sequences useful for the cell proliferative disorder specific analysis of said gene as well as methods, assays and kits thereof.

Abstract: The invention provides methods and nucleic acids for detecting, differentiating or distinguishing between colon cell proliferative disorders as well as therapy thereof by analysis of the gene EYA4 and its promoter and regulatory sequences. The invention further provides novel nucleic acid sequences useful for the cell proliferative disorder specific analysis of said gene as well as methods, assays and kits thereof.

Abstract: Provided are methods and nucleic acids for detecting, differentiating or distinguishing between colon cell proliferative disorders by analysis of one or more of the genes Versican, TPEF, H-Cadherin, Calcitonin, and EYA4. Further provided are novel nucleic acid sequences useful for the cell proliferative disorder specific analysis of said genes as well as methods, assays and kits thereof.

Abstract: The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for predicting the disease free survival and/or response of a subject with a cell proliferative disorder of the breast tissues, to endocrine treatment.

Abstract: The present invention relates to chemically modified genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for ascertaining genetic and/or epigenetic parameters of genes for use in characterisation, classification, differentiation, diagnosis and therapy of prostate lesions.

Abstract: The invention describes a method for amplifying nucleic acids, such as DNA with means of an enzymatic amplification step, such as a polymerase chain reaction, specified for template nucleic acids of low complexity, e.g. pre-treated DNA, like but not limited to DNA pre-treated with bisulfite is disclosed. The invention is based on the use of specific oligo-nucleotide primer molecules to solely amplify specific pieces of DNA. It is disclosed how to optimize the primer design for a PCR if the template DNA is of low complexity.

Abstract: The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for ascertaining genetic and/or epigenetic parameters of genes for use in the differentiation, diagnosis, treatment and/or monitoring of colon cell proliferative disorders, or the predisposition to colon cell proliferative disorders.

Abstract: The invention provides methods and nucleic acids for detecting, differentiating or distinguishing between colon cell proliferative disorders by analysis of one or more of the genes Versican, TPEF, H-Cadherin, Calcitonin, and EYA4. The invention further provides novel nucleic acid sequences useful for the cell proliferative disorder specific analysis of said genes as well as methods, assays and kits thereof.

Abstract: Aspects of the present invention provide compositions and methods for prognosis of, and/or predicting the estrogen treatment outcome of breast cell proliferative disorder patients, and in particular of patients with breast carcinoma. In preferred embodiments, this is achieved, at least in part, by determining the expression level of PITX2, and/or the genetic or the epigenetic modifications of the genomic DNA associated with the gene PITX2. Additional aspects of the invention provide novel sequences, oligomers (e.g., oligonucleotides or peptide nucleic acid (PNA)-oligomers), and antibodies, which have substantial utility in the described inventive methods and compositions.

Abstract: The disclosed invention provides methods and computer program products for the improved verification and controlling of assays for the analysis of nucleic acid variations by means of statistical process control. The invention is characterised in that variables of each experiment are monitored by measuring deviations of said variables from a reference data set and wherein said experiments or batches thereof are indicated as unsuitable for further interpretation if they exceed predetermined limits.

Abstract: A method for epigenetic knowledge generation which designs and synthesizes the chemical and/or biological components that determine the epigenetic parameters to be selected and measured is described. The value of these epigenetic parameters is determined, the steps of this procedure repeated and finally the results are stored. The present invention relates to a method of epigenetic knowledge generation comprising the steps of: a. selecting epigenetic parameters of interest; b. designing the chemical and/or biological components of the epigenetic measurement system, wherein the chemical and/or biological components determine the epigenetic parameters to be measured; c. synthesizing the variable chemical and/or biological components; d. measuring the value of the epigenetic parameters using the chemical and/or biological components; e. storing the results obtained by measurement; f. defining a subset of epigenetic parameters of interest based on the measurements; g. repeating steps a-d.

Abstract: The invention provides methods and nucleic acids for detecting, differentiating or distinguishing between colon cell proliferative disorders as well as therapy thereof by analysis of the gene EYA4 and its promoter and regulatory sequences. The invention further provides novel nucleic acid sequences useful for the cell proliferative disorder specific analysis of said gene as well as methods, assays and kits thereof.

Abstract: The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for ascertaining genetic and/or epigenetic parameters of genes for use in the differentiation, diagnosis, treatment and/or monitoring of hematopoietic cell proliferative disorders, or the predisposition to hematopoietic cell proliferative disorders.

Abstract: The present invention relates to the chemically modified nucleic acid sequences of genomic DNA, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomnic DNA, as well as to a method for ascertaining genetic and/or epigenetic parameters of genes for the characterizing, classifying and/or differentiating of renal and prostate carcinomas.

Abstract: A method for selecting epigenetic features includes receiving an epigenetic feature data set for a plurality of epigenetic features of interest. The epigenetic feature data set is grouped in disjunct classes of interest. Epigenetic features of interest and/or combinations of epigenetic features of interest are selected that are relevant for epigenetically-based prediction based on corresponding epigenetic feature data. A new set of epigenetic features of interest is defined based on the relevant epigenetic features of interest and/or combinations of epigenetic features of interest.

Abstract: The present invention relates to chemically modified genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for ascertaining genetic and/or epigenetic parameters of genes for use in characterisation, classification, differentiation, diagnosis and therapy of prostate lesions.

Abstract: This invention concerns systems for collecting and storing epigenetic and phenotypic information about samples in order to measure and analyse tissue samples and/or cell lines, where the epigenetic parameter is DNA methylation and the phenotypic parameters describe an individual. The method includes parameters such as the diagnosis of diseases and/or drug resistance, wherein the correlation of the epigenetic with the phenotypic parameters is done substantially without human intervention.